Latin America Pharmaceutical Products CMO Market Analysis & Forecast: 2026-2033
The Latin America pharmaceutical products CMO market is anticipated to grow at a CAGR of 6.95% with USD 25.5 Bn in 2026 and is expected to reach USD 38.46 Bn in 2033. The Latin America pharmaceutical contract manufacturing market is growing due to the increasing outsourcing of biologics production, the use of AI-based technologies to improve manufacturing processes, and the availability of ESG-focused funding that helps companies invest at lower costs. These factors are helping pharmaceutical manufacturers (Brazil, USD7.92 Bn) become more efficient, competitive, and attractive to global pharma companies.
Contract Manufacturing Services (CMO) is projected to account for the largest share of service type in 2026, representing approximately 60% of the total volume. Driven by economic, as well as regulatory factors that collectively reinforce the outsourcing model across the regional pharmaceutical ecosystem.
The growing burden of the region on chronic as well as infectious diseases, as of 2025, a study by Unicamp found that 45% of Brazilian adults aged 18 and older have at least one chronic noncommunicable disease. This has sustained an uninterrupted demand for large-scale pharmaceutical production, ranging from solid oral dosage forms and injectables to biologics and biosimilars.
Government authorities as well as public health institutions across Latin America continue to mandate reliable and affordable drug supply chains, which in turn compels both multinational pharmaceutical companies and local manufacturers to leverage CMO partnerships for capacity optimization and cost efficiency.
To learn more about this report, Request Free Sample
Based on product type, small molecule drugs dominates the market, accounting for a significant 55% share in 2026. Owing to their deeply established manufacturing infrastructure, widespread therapeutic application, as well as the longstanding regulatory familiarity that contract manufacturing organizations across Brazil, Mexico, Argentina, and Colombia have developed over decades of pharmaceutical production. Mexico exported pharmaceutical products mainly to the United States, with exports worth about USD 1.18 billion. Other major export destinations were Colombia (USD 254.3 million), Canada (USD 206.5 million), Panama (USD 120.1 million), and Brazil (USD 94.1 million).
The dominance of small molecule drugs is not a coincidental outcome but rather the result of a well-entrenched pharmaceutical ecosystem that has historically been built upon chemical synthesis as well as formulation technologies. Countries including Brazil, through its national pharmaceutical regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária), have developed strong frameworks that facilitate the approval and commercialization of small molecule drug formulations, which in turn encourages multinational pharmaceutical companies to outsource their manufacturing activities to local and regional CMOs.
Based on therapeutic area, oncology dominates the market, accounting for a significant 30% share in 2026. Owing to the rapidly escalating cancer burden across Latin American nations, the high complexity of oncology drug formulations, as well as the high reliance of pharmaceutical companies on contract manufacturing organizations to handle technically demanding biologics as well as cytotoxic drug production.
The high prevalence of cancer across the region has placed enormous pressure on healthcare systems, prompting both multinational as well as regional pharmaceutical companies to partner extensively with CMOs that possess specialized capabilities in sterile manufacturing. Argentina has a cancer incidence rate of 218 cases per 100,000 people each year (excluding melanoma skin cancer). According to the International Agency for Research on Cancer (IARC), Argentina is considered a country with a medium to high cancer incidence as well as ranks seventh in the Americas for cancer incidence.
According to the Pan American Health Organization (PAHO), cancer has become one of the leading causes of mortality across Latin America and the Caribbean, with the region reporting millions of new cancer cases annually, particularly in Brazil, Mexico, Argentina, and Colombia, which collectively represent the major pharmaceutical manufacturing hubs of the region.
Based on end user, pharmaceutical companies dominates the market, accounting for a significant 45% share in 2026. Their long-established reliance on contract manufacturing organizations to simplify production, manage operational costs, as well as maintain compliance with stringent regulatory frameworks across the region are the growth inducing factors.
The deeply entrenched presence of major multinational pharmaceutical corporations in countries including Brazil, Mexico, Argentina, Colombia, etc., has historically driven consistent and high-volume outsourcing demand. Between April 2026 and May 2026, Brazil's pharmaceutical product exports increased by USD 14.1 million (15.2%), rising from USD 93.2 million to USD 107 million.
These companies work under complex portfolio management strategies that require them to balance branded product launches, lifecycle management of mature drugs, as well as compliance with both local health authority requirements and international standards such as those set by the Pan American Health Organization (PAHO).
Continuous Manufacturing (CM) is a modern way of making pharmaceutical products where materials move continuously through the production process instead of being made in separate batches. This helps companies produce medicines faster, improve product quality, reduce waste, and use less factory space. Common CM technologies include continuous blending, wet and dry granulation, direct compression, and hot melt extrusion. In Latin America, companies such as Eurofarma (Brazil), Laboratorio Chile (Chile), Siegfried (Argentina), Sanfer (Mexico), and Procaps Group (Colombia) have adopted these technologies between 2020 and 2023 for both pilot and commercial production.
The use of Continuous Manufacturing has delivered strong results across the region. Eurofarma reduced its production cycle time by 35–40%, while continuous monitoring lowered out-of-specification (OOS) batches by around 60%. Companies also achieved 20–25% lower energy consumption and reduced work-in-progress inventory by about 30%. In addition, CM supports compliance with FDA Process Analytical Technology (PAT) guidelines, helping manufacturers improve efficiency and expand export opportunities.
Biologics and biosimilar manufacturing use advanced technologies to produce complex medicines including monoclonal antibodies as well as other biological drugs. These technologies include stainless steel and single-use bioreactors, cell culture systems, protein purification, freeze-drying, as well as aseptic filling. As demand for biosimilars grows, many pharmaceutical companies in Latin America are increasing investments in these manufacturing facilities.
For example, Bionovis (Brazil) invested around USD 250 million in a biopharmaceutical manufacturing facility with 5,000L and 10,000L bioreactors. This helped reduce Brazil's dependence on imported APIs for Infliximab by 40% and created more than 2,000 jobs. Libbs Farmacêutica (Brazil) also upgraded its biologics production by adopting advanced aseptic filling technology, reducing contamination risk by 99.9%, achieving WHO GMP certification, and expanding biosimilar exports to 12+ countries.
|
Current Event |
Description and its Impact |
|
Expansion of Local Pharmaceutical Manufacturing Policies of Brazil (2024–2026) |
|
|
Stronger GMP Compliance and Regulatory Harmonization Across Latin America (2024–2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Brazil account 40% market share in 2026, Brazil has a well-established pharmaceutical industry supported by a strong regulatory framework. As of December 2023, the country had 10,125 medicines with marketing authorization, of which 80.1% (8,201) had a single active ingredient. This large number of approved medicines shows the maturity of pharmaceutical market of Brazil and supports its position as an important manufacturing and pharmaceutical hub in Latin America.
Brazil's national regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária), has progressively harmonized its pharmaceutical manufacturing standards with those of the U.S. Food and Drug Administration (FDA), enabling Brazilian CMOs to easy navigate dual regulatory compliance requirements that North American clients demand.
According to Brazil's Ministry of Economy, the country houses over 500 pharmaceutical manufacturing establishments, a significant proportion of which have expanded their contract manufacturing service portfolios explicitly targeting North American pharmaceutical corporations.
Some of the major key players in Latin America pharmaceutical products CMO market includes, BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 25.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.95% | 2033 Value Projection: | USD 38.46 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
